ENGN | enGene Holdings Inc. Common Stock Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	7.04 - 8.06
52 Week Range	4.42 - 18.40
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	204,174
Average Volume	142,656
Shares Outstanding	50,976,677
Market Cap	381,815,311
Sector	Healthcare
Industry	Biotechnology
IPO Date	2022-02-01

Valuation
Profitability
Growth
Health
P/E Ratio	-5.13
Forward P/E Ratio	N/A
EPS	-1.46
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	31
Country	Canada
Website	ENGN

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

*Chart delayed

Analyzing fundamentals for ENGN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong. For more detailed analysis please see ENGN Fundamentals page.

Watching at ENGN technicals we can see that long-term trend is bearish, while middle-term trend is bullish, as well as bullish short-term trend. More technicals details can be found on ENGN Technicals page.